Market Place
Sanofi buys OTC rights in US for Roche’s flu treatment Tamiflu
French drugmaker Sanofi has signed a rights deal with Roche for ‘Tamiflu’ in the United States. The deal gives Sanofi exclusive over-the-counter (OTC) rights to Tamiflu in the US.
Tamiflu is used for the prevention and treatment of flu.
“[A] successful switch of Tamiflu to OTC would support our global cough and cold strategy by expanding into flu with a sustainable point of difference in the market,” Alan Main, executive vice president of Sanofi consumer healthcare, said in a statement. Currently available OTC flu products only alleviate symptoms, while Tamiflu deals with the virus itself.
Roche will focus more on its newly approved Xofluza. With just a single dose, Xofluza could alleviate flu symptoms as fast as Tamiflu, which usually requires twice daily dosing for five days.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
